Literature DB >> 16682426

Control of matrix metalloproteinase production in human intestinal fibroblasts by interleukin 21.

G Monteleone1, R Caruso, D Fina, I Peluso, V Gioia, C Stolfi, M C Fantini, F Caprioli, R Tersigni, L Alessandroni, T T MacDonald, F Pallone.   

Abstract

BACKGROUND: T cell-mediated immunity plays a central part in the pathogenesis of tissue damage in inflammatory bowel disease (IBD). The mechanism by which T cells mediate tissue damage during IBD remains unclear, but evidence indicates that T cell-derived cytokines stimulate fibroblasts to synthesise matrix metalloproteinases (MMPs), which then mediate mucosal degradation. We have previously shown that, in IBD, there is high production of interleukin (IL) 21, a T cell-derived cytokine, which enhances Th1 activity. AIM: To investigate whether IL21 controls MMP production by intestinal fibroblasts.
METHODS: IL21 receptor (IL21R) was evaluated in intestinal fibroblasts by reverse transcriptase-polymerase chain reaction (RT-PCR) and western blotting. Fibroblasts were stimulated with IL21 and MMPs were evaluated by RT-PCR and western blotting. The effect of a neutralising IL21R fusion protein (IL21R/Fc) on the induction of MMPs in fibroblasts stimulated with IBD lamina propria mononuclear cell (LPMC) supernatants was also evaluated.
RESULTS: Intestinal fibroblasts constitutively express both IL21R and the common gamma chain receptor, which are necessary for IL21-driven signalling. IL21 enhances fibroblast production of MMP-1, MMP-2, MMP-3 and MMP-9, but not tissue inhibitors of MMP-1 and MMP-2. Moreover, IL21 synergises with tumour necrosis factor alpha to increase synthesis of MMP synthesis. IL21 enhances MMP secretion without affecting gene transcription and protein synthesis. IBD LPMC supernatants stimulate MMP secretion by intestinal fibroblasts, and this effect is partly inhibited by IL21R/Fc.
CONCLUSIONS: These results suggest that fibroblasts are a potential target of IL21 in the gut and that IL21 controls MMP secretion by fibroblasts.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16682426      PMCID: PMC1856468          DOI: 10.1136/gut.2006.093187

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  35 in total

1.  Interleukin-22, a member of the IL-10 subfamily, induces inflammatory responses in colonic subepithelial myofibroblasts.

Authors:  Akira Andoh; Zhuobin Zhang; Osamu Inatomi; Sanae Fujino; Yasuyuki Deguchi; Yoshio Araki; Tomoyuki Tsujikawa; Katsuyuki Kitoh; Shokei Kim-Mitsuyama; Atsushi Takayanagi; Nobuyoshi Shimizu; Yoshihide Fujiyama
Journal:  Gastroenterology       Date:  2005-09       Impact factor: 22.682

2.  Enhancing Lamina propria Th1 cell responses with interleukin 12 produces severe tissue injury.

Authors:  G Monteleone; T T MacDonald; N C Wathen; F Pallone; S L Pender
Journal:  Gastroenterology       Date:  1999-11       Impact factor: 22.682

3.  Differential expression of matrix metalloproteinases 2 and 9 by glial Müller cells: response to soluble and extracellular matrix-bound tumor necrosis factor-alpha.

Authors:  G Astrid Limb; Julie T Daniels; Robert Pleass; David G Charteris; Philip J Luthert; Peng T Khaw
Journal:  Am J Pathol       Date:  2002-05       Impact factor: 4.307

4.  Interleukin-21 is a growth and survival factor for human myeloma cells.

Authors:  Anne-Tove Brenne; Torstein Baade Ro; Anders Waage; Anders Sundan; Magne Borset; Henrik Hjorth-Hansen
Journal:  Blood       Date:  2002-05-15       Impact factor: 22.113

5.  Posttranscriptional stimulation of endothelial cell matrix metalloproteinases 2 and 1 by endothelioma cells.

Authors:  G Taraboletti; L Sonzogni; V Vergani; G Hosseini; R Ceruti; C Ghilardi; A Bastone; E Toschi; P Borsotti; E Scanziani; R Giavazzi; M S Pepper; W G Stetler-Stevenson; M R Bani
Journal:  Exp Cell Res       Date:  2000-08-01       Impact factor: 3.905

Review 6.  Manipulation of cytokines in the management of patients with inflammatory bowel disease.

Authors:  G Monteleone; T T MacDonald
Journal:  Ann Med       Date:  2000-11       Impact factor: 4.709

7.  Imbalance of stromelysin-1 and TIMP-1 in the mucosal lesions of children with inflammatory bowel disease.

Authors:  R B Heuschkel; T T MacDonald; G Monteleone; M Bajaj-Elliott; J A Smith; S L Pender
Journal:  Gut       Date:  2000-07       Impact factor: 23.059

8.  Differential expression of matrix metalloproteinases and their tissue inhibitors in colon mucosa of patients with inflammatory bowel disease.

Authors:  B von Lampe; B Barthel; S E Coupland; E O Riecken; S Rosewicz
Journal:  Gut       Date:  2000-07       Impact factor: 23.059

9.  Upregulation of matrix metalloproteinases in a model of T cell mediated tissue injury in the gut: analysis by gene array and in situ hybridisation.

Authors:  M T Salmela; T T MacDonald; D Black; B Irvine; T Zhuma; U Saarialho-Kere; S L F Pender
Journal:  Gut       Date:  2002-10       Impact factor: 23.059

10.  The common gamma chain (gamma c) is a required signaling component of the IL-21 receptor and supports IL-21-induced cell proliferation via JAK3.

Authors:  Tania Habib; Shantha Senadheera; Kenneth Weinberg; Kenneth Kaushansky
Journal:  Biochemistry       Date:  2002-07-09       Impact factor: 3.162

View more
  63 in total

Review 1.  Interleukin-23 and T helper 17-type responses in intestinal inflammation: from cytokines to T-cell plasticity.

Authors:  Peter J Morrison; Sarah J Ballantyne; Marika C Kullberg
Journal:  Immunology       Date:  2011-06-02       Impact factor: 7.397

Review 2.  Inflammatory bowel disease: Moving toward a stem cell-based therapy.

Authors:  Giacomo Lanzoni; Giulia Roda; Andrea Belluzzi; Enrico Roda; Gian Paolo Bagnara
Journal:  World J Gastroenterol       Date:  2008-08-07       Impact factor: 5.742

3.  TGF-β limits IL-33 production and promotes the resolution of colitis through regulation of macrophage function.

Authors:  Reena Rani; Alan G Smulian; David R Greaves; Simon P Hogan; De'Broski R Herbert
Journal:  Eur J Immunol       Date:  2011-05-27       Impact factor: 5.532

Review 4.  Interleukin-21: a double-edged sword with therapeutic potential.

Authors:  Rosanne Spolski; Warren J Leonard
Journal:  Nat Rev Drug Discov       Date:  2014-04-22       Impact factor: 84.694

5.  IL-21R is essential for epicutaneous sensitization and allergic skin inflammation in humans and mice.

Authors:  Haoli Jin; Michiko K Oyoshi; Yi Le; Teresa Bianchi; Suresh Koduru; Clinton B Mathias; Lalit Kumar; Séverine Le Bras; Deborah Young; Mary Collins; Michael J Grusby; Joerg Wenzel; Thomas Bieber; Marianne Boes; Leslie E Silberstein; Hans C Oettgen; Raif S Geha
Journal:  J Clin Invest       Date:  2008-12-15       Impact factor: 14.808

Review 6.  Regulation and function of proinflammatory TH17 cells.

Authors:  Gustavo J Martinez; Roza I Nurieva; Xuexian O Yang; Chen Dong
Journal:  Ann N Y Acad Sci       Date:  2008-11       Impact factor: 5.691

7.  The increased mucosal mRNA expressions of complement C3 and interleukin-17 in inflammatory bowel disease.

Authors:  T Sugihara; A Kobori; H Imaeda; T Tsujikawa; K Amagase; K Takeuchi; Y Fujiyama; A Andoh
Journal:  Clin Exp Immunol       Date:  2010-01-19       Impact factor: 4.330

8.  IL-21 receptor signalling partially mediates Th2-mediated allergic airway responses.

Authors:  S Lajoie; I Lewkowich; N S Herman; A Sproles; J T Pesce; T A Wynn; M J Grusby; Q Hamid; M Wills-Karp
Journal:  Clin Exp Allergy       Date:  2014-07       Impact factor: 5.018

Review 9.  Involvement of interleukin-15 and interleukin-21, two gamma-chain-related cytokines, in celiac disease.

Authors:  Daniela De Nitto; Ivan Monteleone; Eleonora Franzè; Francesco Pallone; Giovanni Monteleone
Journal:  World J Gastroenterol       Date:  2009-10-07       Impact factor: 5.742

Review 10.  Interleukin-23 and Th17 cells in the control of gut inflammation.

Authors:  Ivan Monteleone; Francesco Pallone; Giovanni Monteleone
Journal:  Mediators Inflamm       Date:  2009-05-27       Impact factor: 4.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.